July 19, 2011 -- Chongqing Zhifei Biological Products announced it will not pursue a plan to acquire Bilthoven Biologicals, a Dutch vaccine maker, explaining that the transaction was too risky. According to Zhifei, Bilthoven’s plans and operational methods were not what it expected. In May of this year, Zhifei announced a $93 million takeover of Bilthoven’s operations (see story), which it positioned as a means of giving itself a foothold in Europe. More details....
Stock Symbol: (SHE: 300122)
